CM338
/ Keymed Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 08, 2024
Single Ascending Dose Study of CM338 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=66 | Completed | Sponsor: Keymed Biosciences Co.Ltd | Recruiting ➔ Completed
Trial completion
October 15, 2024
Multiple Ascending Dose Study of CM338 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Completed
Trial completion
July 31, 2023
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
(clinicaltrials.gov)
- P2 | N=70 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease
March 20, 2023
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
(clinicaltrials.gov)
- P2 | N=70 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd
New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
May 12, 2022
Multiple Ascending Dose Study of CM338 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd
New P1 trial
1 to 5
Of
5
Go to page
1